We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AmerisourceBergen (ABC) Rewards Investors With Dividend Hike
Read MoreHide Full Article
AmerisourceBergen Corporation’s board of directors has approved a 4% hike in cash dividend per share. The revised dividend of 38 cents will be paid on Dec 4, 2017 to shareholders of record as of Nov 20, 2017.
Further, we believe that AmerisourceBergen will benefit from generics growth in the long run. We note that the company is well positioned to ensure that products will reach the market and that patients will have access to traditional and complex new therapies.
Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to care, improved economic conditions and population demographics, introduction of new innovative drugs like hepatitis C drugs, and a persistent brand pricing environment should drive growth. Moreover, the company’s focus on specialty drugs bodes well.
On the flip side, cutthroat competition in the niche space is an additional concern. AmerisourceBergen operates in a highly competitive pharmaceutical distribution and related health-care services market. The company’s primary competitors are national generic and regional distributors. The space is witnessing consolidation of customers and manufacturers, globalization and increasing quality along with regulatory challenges. The company also faces threats from manufacturers, chain drugstores, specialty distributors and packaging and health care technology companies.
The company, based in Chesterbrook, PA, is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes.
Zacks Rank & Key Picks
AmerisourceBergen currently has a Zacks Rank #3 (Hold).
PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter’s 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017, up 216.7% year over year. The company’s revenues in the quarter increased almost 4.1% year over year to $74.1 million.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
AmerisourceBergen (ABC) Rewards Investors With Dividend Hike
AmerisourceBergen Corporation’s board of directors has approved a 4% hike in cash dividend per share. The revised dividend of 38 cents will be paid on Dec 4, 2017 to shareholders of record as of Nov 20, 2017.
Further, we believe that AmerisourceBergen will benefit from generics growth in the long run. We note that the company is well positioned to ensure that products will reach the market and that patients will have access to traditional and complex new therapies.
Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to care, improved economic conditions and population demographics, introduction of new innovative drugs like hepatitis C drugs, and a persistent brand pricing environment should drive growth. Moreover, the company’s focus on specialty drugs bodes well.
On the flip side, cutthroat competition in the niche space is an additional concern. AmerisourceBergen operates in a highly competitive pharmaceutical distribution and related health-care services market. The company’s primary competitors are national generic and regional distributors. The space is witnessing consolidation of customers and manufacturers, globalization and increasing quality along with regulatory challenges. The company also faces threats from manufacturers, chain drugstores, specialty distributors and packaging and health care technology companies.
The company, based in Chesterbrook, PA, is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes.
Zacks Rank & Key Picks
AmerisourceBergen currently has a Zacks Rank #3 (Hold).
A few better-ranked medical stocks are PetMed Express, Inc. (PETS - Free Report) , Luminex Corporation and Intuitive Surgical, Inc. (ISRG - Free Report) . While PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter’s 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017, up 216.7% year over year. The company’s revenues in the quarter increased almost 4.1% year over year to $74.1 million.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>